Cargando…
Non-viral approaches for gene therapy and therapeutic genome editing across the blood–brain barrier
The success of brain-targeted gene therapy and therapeutic genome editing hinges on the efficient delivery of biologics bypassing the blood–brain barrier (BBB), which presents a significant challenge in the development of treatments for central nervous system disorders. This is particularly the case...
Autores principales: | Xie, Ruosen, Wang, Yuyuan, Burger, Jacobus C., Li, Dongdong, Zhu, Min, Gong, Shaoqin |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer Nature Singapore
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10357415/ https://www.ncbi.nlm.nih.gov/pubmed/37485250 http://dx.doi.org/10.1007/s44258-023-00004-0 |
Ejemplares similares
-
A biodegradable nanocapsule delivers a Cas9 ribonucleoprotein complex for in vivo genome editing
por: Chen, Guojun, et al.
Publicado: (2019) -
Editing a gateway for cell therapy across the blood–brain barrier
por: Achón Buil, Beatriz, et al.
Publicado: (2022) -
Non-viral liposome-mediated transfer of brain-derived neurotrophic factor across the blood-brain barrier
por: Xing, Ying, et al.
Publicado: (2016) -
Passage of immunomodulators across the blood-brain barrier.
por: Stitt, J. T.
Publicado: (1990) -
Passage of parasites across the blood-brain barrier
por: Masocha, Willias, et al.
Publicado: (2012)